Mark Clark
Austin, TXNPI 1376568691
Payments from drug & device makers
Across 167 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Boehringer Ingelheim$615
- Actelion Pharmaceuticals US, Inc.$244
- Philips North America LLC$227
- Genentech USA, Inc.$169
- AstraZeneca$165
- plus $331 from 7 others
What the payments were for
- Food & beverage$2,823100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 66 | $1,073 |
| Boehringer Ingelheim | 27 | $615 |
| Actelion Pharmaceuticals US, Inc. | 18 | $244 |
| Philips North America LLC | 17 | $227 |
| Genentech USA, Inc. | 9 | $169 |
| AstraZeneca(2 entities) | 11 | $165 |
| Regeneron Healthcare Solutions, Inc. | 4 | $114 |
| Johnson & Johnson | 6 | $84 |
| Mylan Specialty L.p. | 5 | $67 |
| AbbVie | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Sanofi | 1 | $16 |
| Circassia Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$117
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 14 | $47,601 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.